In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Andreas Obermair and Monika Janda to discuss the FeMMe trial.

Highlights:

feMMe was a randomised phase 2 trial testing LNG-IUD alone or in combination with a weight loss intervention or metformin for endometrial hyperplasia with atypia or stage 1 endometrial cancer.

Overall complete pathological response at 6 month was 61%.

Women with endometrial hyperplasia with atypia responded much better than women with endometrial cancer.

Weight loss achieved was moderate and BMI was not associated with response – more work on weight loss interventions needed.